Literature DB >> 9103455

Constitutive shedding of both p55 and p75 murine TNF receptors in vivo.

J K Pinckard1, K C Sheehan, C D Arthur, R D Schreiber.   

Abstract

Recently, we reported the generation and characterization of hamster mAbs specific for the murine p55 and p75 TNF receptors. Upon characterizing these mAbs in vivo, we discovered that administration of TNF receptor-specific mAb to normal mice resulted in the linear accumulation of the appropriate class of soluble TNF receptor in the circulation. The mechanism underlying soluble receptor accumulation was found to be due to an abrogation of the clearance of constitutively shed soluble receptor by receptor-specific mAb. Levels of p55 or p75 accumulated in the presence of nonblocking, nonagonistic TNF receptor mAb were capable of inhibiting murine TNF-induced responses in vivo. These results document that both p55 and p75 are constitutively shed in substantial amounts in vivo and suggest that the process of constitutive TNF receptor shedding plays an important role in regulating TNF activity under physiologic conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103455

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  FEBS Lett       Date:  2011-04-15       Impact factor: 4.124

Review 2.  B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature.

Authors:  Ozlem Pala; Alain Diaz; Bonnie B Blomberg; Daniela Frasca
Journal:  Clin Ther       Date:  2018-05-23       Impact factor: 3.393

3.  Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia.

Authors:  G I Botchkina; M E Meistrell; I L Botchkina; K J Tracey
Journal:  Mol Med       Date:  1997-11       Impact factor: 6.354

4.  Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide.

Authors:  C Y Chiang; G Kyritsis; D T Graves; S Amar
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

5.  IL-1beta augments TNF-alpha-mediated inflammatory responses from lung epithelial cells.

Authors:  Sara Saperstein; Linlin Chen; David Oakes; Gloria Pryhuber; Jacob Finkelstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

6.  Spread of infection and lymphocyte depletion in mice depends on polymerase of influenza virus.

Authors:  Gülsah Gabriel; Karin Klingel; Oliver Planz; Katja Bier; Astrid Herwig; Martina Sauter; Hans-Dieter Klenk
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

7.  Murine cytomegalovirus infection inhibits tumor necrosis factor alpha responses in primary macrophages.

Authors:  Daniel L Popkin; Herbert W Virgin
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 8.  A role for tumor necrosis factor-α in ischemia and ischemic preconditioning.

Authors:  Orla Watters; John J O'Connor
Journal:  J Neuroinflammation       Date:  2011-08-02       Impact factor: 8.322

9.  Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.

Authors:  Matthew M Cousins; Theresa P Devasia; Christopher M Maurino; Justin Mikell; Matthew J Schipper; Ravi K Kaza; Theodore S Lawrence; Kyle C Cuneo; Yuni K Dewaraja
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

10.  Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases.

Authors:  Sofia Xanthoulea; Manolis Pasparakis; Stavroula Kousteni; Cord Brakebusch; David Wallach; Jan Bauer; Hans Lassmann; George Kollias
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.